Entering text into the input field will update the search result below

Amneal Pharmaceuticals enters US biosimilar market with FDA nod for RELEUKOTM

Mar. 01, 2022 4:44 PM ETAMRXBy: Jessica Kuruthukulangara, SA News Editor1 Comment
  • Amneal Pharmaceuticals (NYSE:AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.
  • The product will be marketed under the proprietary name RELEUKOTM.
  • RELEUKOTM was developed in collaboration with Kashiv Biosciences in Chicago, Illinois.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

GrowthFan profile picture
FDA clearance for a generic bio similar drug opens up a significant new revenue stream for Amneal. We will see how successful they are in entering this significant chemo therapy market. But, the stock AMRX, appears incredibly cheap at this price level.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.